Deciphering the selective androgen receptor modulators paradigm

Bibliography

• Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1-28
   PubMed Web of Science ®Google Scholar
• Perez-Lopez FR, Larrad-Mur L, Kallen A, Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 2010;17:511-31
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Shiina H, Kawano H, Androgen receptor functions in male and female physiology. J. Steroid. Biochem. Mol. Biol 2008;109:236-41
   PubMed Web of Science ®Google Scholar
• Liverman CD, Blazer DG. Testosterone and aging: clinical research directions. Institute of Medicine report Natl Acad Press; Washington, D.C: 2004
   Google Scholar
• Diamond TH. Pharmacotherapy of osteoporosis in men. Exp Opin Pharmacother 2005;6:45-58
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Vandenput L, Boonen S. Androgen and bone. Endocr Rev 2004;25:389-425
   PubMed Web of Science ®Google Scholar
• Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril 2004;82:273-89
   PubMed Web of Science ®Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, Low-dose estradiol spray to treat vasomotoe symptoms: a randomized controlled trial. Obstet Gynecol 2005;105:944-52
   PubMed Web of Science ®Google Scholar
• Bocklandt S, Vilain E. Sex differences in brain and behavior: hormones versus genes. Adv Genet 2007;59:245-66
   PubMed Web of Science ®Google Scholar
• Leder B. Gonadal steroids and bone metabolism in men. Curr Opin Endocrinol Diabetes Obes 2007;14:241-6
   PubMedGoogle Scholar
• Chang C, Saltzman A, Yeh S, Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995;5:97-125
   PubMed Web of Science ®Google Scholar
• Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007;21:2855-63
   PubMed Web of Science ®Google Scholar
• Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009;63:142-8
   PubMed Web of Science ®Google Scholar
• Claessens F, Denayer S, Van Tilborgh N, Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008;6:e008
   PubMedGoogle Scholar
• Alen P, Claessens F, Verhoeven G, The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 1999;19:6085-97
   PubMed Web of Science ®Google Scholar
• Bevan CL, Hoare S, Claessens F, The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-92
   PubMed Web of Science ®Google Scholar
• Gao T, Marcelli M, McPhaul MJ. Transcriptional activation and transient expression of the human androgen receptor. J Steroid Biochem Mol Biol 1996;59:9-20
   PubMed Web of Science ®Google Scholar
• Jenster G, van der Korput HA, van Vroonhoven C, Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5:1396-404
   PubMed Web of Science ®Google Scholar
• Simental JA, Sar M, Lane MV, Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266:510-18
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200
   PubMed Web of Science ®Google Scholar
• Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 2003;78:175-85
   PubMed Web of Science ®Google Scholar
• Ylikomi T, Bocquel MT, Berry M, Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. Embo J 1992;11:3681-94
   PubMed Web of Science ®Google Scholar
• Gioeli D, Black BE, Gordon V, Weber MJ. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006;20:503-15
   PubMed Web of Science ®Google Scholar
• Tilley WD, Buchanan G, Hickey TE, Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-85
   PubMed Web of Science ®Google Scholar
• Wang C, Uchida T. Androgen receptor gene mutations inprostate cancer. Nippon Hinyokika Gakkai Zasshi 1997;88:550-6
   PubMedGoogle Scholar
• Tanner TM, Denayer S, Geverts B, A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci 2010;67(11):1919-27
   PubMed Web of Science ®Google Scholar
• Wong C, Kelce WR, Sar M, Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 1995;270:19998-20003
   PubMed Web of Science ®Google Scholar
• Kallio PJ, Poukka H, Moilanen A, Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol 1995;9:1017-28
   PubMed Web of Science ®Google Scholar
• Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev 1993;14:651-8
   PubMed Web of Science ®Google Scholar
• Ye X, Han SJ, Tsai SY, Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci USA 2005;102:9487-92
   PubMed Web of Science ®Google Scholar
• Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998;273:92-101
   PubMed Web of Science ®Google Scholar
• Thompson J, Saatcioglu F, Janne OA. et al. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol 2001;15:923-35
   PubMed Web of Science ®Google Scholar
• Quigley CA, Tan JA, He B, Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH2- and carboxyl-terminal interaction. Mech Ageing Dev 2004;125:683-95
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
   PubMed Web of Science ®Google Scholar
• Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med 2007;120:835-40
   PubMed Web of Science ®Google Scholar
• Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502-21
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006;65:275-81
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff R, ISA ISSAM EAU EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009;21:1-8
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, ISA ISSAM EAU EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12
   PubMed Web of Science ®Google Scholar
• Zhi L, Martinborough E. Selective androgen receptor modulators (SARMs). Annu Rep Med Chem 2001;36:169-80
   Web of Science ®Google Scholar
• Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrino Metab 1999;84:3459-62
   PubMed Web of Science ®Google Scholar
• Jones JO. Improving selective androgen receptor modulator discovery and preclinical evaluation. Expert Opin Drug Discov 2009;4:981-93
   PubMed Web of Science ®Google Scholar
• Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol 2012;352:79-91
   PubMed Web of Science ®Google Scholar
• Mohler ML, Bohl CE, Jones A, Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009;52:3597-617
   PubMed Web of Science ®Google Scholar
• Rodolfo C, Philip T. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top in Med Chem 2006;6:245-70
   PubMed Web of Science ®Google Scholar
• Mohler ML, Nair VA, Hwang DJ, Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates. Expert Opin Ther Pat 2005;15:1565-85
   Web of Science ®Google Scholar
• Zhang X, Lanter JC, Sui Z. Recent advances in the development of selective androgen receptor modulators. Expert Opin Ther Pat 2009;19:1239-58
   PubMed Web of Science ®Google Scholar
• Mohler ML, He Y, Hwang DJ, Nonsteroidal tissue selective androgen receptor modulators. Volume 39 In Nuclear Receptors as Drug Targets Wiley-VCH; Weinheim: Germany: 2008. p. 249-304. Chapter 8
   Google Scholar
• Narayanan R, Mohler ML, Bohl CE, Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signaling 2008;6:e010
   PubMedGoogle Scholar
• Dalton JT, Mukherjee A, Zhu Z, Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244(1):1-4
   PubMed Web of Science ®Google Scholar
• Radius Health, Inc. Preparation of oxooxazolidinylbenzonitrile derivatives and analogs for use as selective androgen receptor modulators. WO 2012047617; 2012
   Google Scholar
• Radius Health, Inc. Preparation of oxadiazole compounds as selective androgen receptor modulators. US 20120004270; 2012
   Google Scholar
• Aragon pharmaceuticals. Preparation of spiro thiohydantoin compounds as androgen receptor modulators. WO 2011103202; 2011
   Google Scholar
• The University of British Columbia. Bisphenol derivatives as androgen receptor modulators and their preparation and use for the treatment of diseases. WO 2011082488; 2011
   Google Scholar
• Orion, Co. Preparation of pyrazole- and imidazole-carboxamide derivatives as modulators of androgen receptor. WO 2011051540; 2011
   Google Scholar
• Astrazeneca. Bicyclic derivatives for use in the treatment of androgen receptor associated conditions and their preparation. WO 2009081197; 2009
   Google Scholar
• Sumitomo Chemical. Preparation of 5-aminothiophene derivatives as selective androgen receptor modulators. WO 2010126167; 2010
   Google Scholar
• Radius Health, Inc. Preparation of oxadiazolylalkylindoles as selective androgen receptor modulators. WO 2010118287; 2010
   Google Scholar
• Consiglio Nazionale delle Ricerche Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori. Preparation of aminoalkylamide and oxoimidazolidine derivatives and related compounds as modulators of androgen receptor. WO 2010092546; 2010
   Google Scholar
• University of British Columbia. Diglycidic ether derivatives as androgen receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of cancers. WO 2010000066; 2010
   Google Scholar
• Eli Lilly and Company. Preparation of tetrahydrocyclopenta[b]indole as androgen receptor modulators. WO 2009140448; 2009
   Google Scholar
• Takeda Pharmaceutical. Preparation of N-(4-heterocyclylphenyl) cyclic amine compounds as androgen receptor modulators. WO 2009133861; 2009
   Google Scholar
• Yin D, Gao W, Kearbey JD, Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003;304:1334-40
   PubMed Web of Science ®Google Scholar
• Gao W, Kearbey JD, Nair VA, Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α -reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: New approach for benign prostate hyperplasia. Endocr 2004;145:5420-8
   PubMed Web of Science ®Google Scholar
• Chen J, Hwang DJ, Bohl CE, A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 2005;312:546-53
   PubMed Web of Science ®Google Scholar
• Jones A, Chen J, Hwang DJ, Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocr 2009;150:385-95
   PubMed Web of Science ®Google Scholar
• Kearbey JD, Gao W, Narayanan R, Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 2007;24(2):328-35
   PubMed Web of Science ®Google Scholar
• Jones A, Hwang DJ, Duke CB III, Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther 2010;334:439-48
   PubMed Web of Science ®Google Scholar
• University of Tennessee Research Foundation. Phenoxypropionic acid benzamides and related compounds as selective androgen receptor modulators (SARMs) for treating diabetes, diseases associated with diabetes, and other disorders. WO 2008127717; 2008. study NCT00467844 http://clinicaltrials.gov
   Google Scholar
• News release from GTx, Inc. on June 06, 2011: GTx announces agreement with FDA on Phase III clinical development plan evaluating OstarineTM (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer
   Google Scholar
• GTx announces investigational OstarineTM (MK-2866) met the primary endpoint in the Phase II cancer cachexia clinical trial. Oral podium presentation at the 2009 Annual Meeting of the Endocrine Society; Washington
   Google Scholar
• Ostrowski J, Kuhns JE, Lupisella JA, Pharmacological and X-raystructural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocr 2007;148:4-12
   PubMed Web of Science ®Google Scholar
• Li JJ, Sutton JC, Nirschl A, Discovery of potent and muscle selective androgen receptor modulators (SARMs) through scaffold modifications. J Med Chem 2007;50:3015-25
   PubMed Web of Science ®Google Scholar
• Nirschl AA, Zou Y, Krystek SR Jr, N-Aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem 2009;52:2794-8
   PubMed Web of Science ®Google Scholar
• Edwards JP, Higuchi R, Jones T. Androgen receptor modulator compounds and methods. US 2000 6017924; 2000
   Google Scholar
• Edwards JP, West SJ, Pooley CL, New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 1998;8:745-50
   PubMed Web of Science ®Google Scholar
• Edwards JP, Higuchi RI, Winn DT, Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg Med Chem Lett 1999;9:1003-8
   PubMed Web of Science ®Google Scholar
• Higuchi RI, Edwards JP, Caferro TR, 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg Med Chem Lett 1999;9:1335-40
   PubMed Web of Science ®Google Scholar
• Riedmaier I, Tichopad A, Reiter M, Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol 2009;114:167-73
   PubMed Web of Science ®Google Scholar
• Miner JN, Chang W, Chapman MS, An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocr 2007;148:363-73
   PubMed Web of Science ®Google Scholar
• Martinborough E, Shen Y, Oeveren A, Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem 2007;50:5049-52
   PubMed Web of Science ®Google Scholar
• Vajda EG, Lopez FJ, Rix P, Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal- selective androgen receptor modulator. J Pharmacol Exp Ther 2009;328:663-70
   PubMed Web of Science ®Google Scholar
• Vajda EG, Hogue A, Griffiths KN, Combination Treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats. J Bone Min Res 2009;24:231-40
   PubMed Web of Science ®Google Scholar
• Kudwa AE, Lopez FJ, McGivern RF, A selective androgen receptor modulator enhances male-directed sexual preference, proceptive behavior, and lordosis behavior in sexually experienced, but not sexually naive, female rats. Endocri 2010;15:2659-68
   Web of Science ®Google Scholar
• Ligand presents first-in-human Phase I data on lead SARM molecule LGD-4033. A poster presentation at the 14th International Congress of Endocrinology; Kyoto, Japan
   Google Scholar
• Vajda EG, Marschke K, van Oeveren A, LGD-4033 builds muscle and bone with reduced prostate activity and maybe beneficial in age-related frailty. According to the following link from Ligand. Avaialble from (http://www.ligand.com/upload/File/publications/SARM%20LGD 4033%20Poster%20November%202009.pdf)
   Google Scholar
• Basaria S, Collins L, Sheffield-Morre M, Safety and tolerability of LGD-4033, a novel non-steroidal oral selective androgen receptor modulator (SARM), in healthy men. J Gerontol A Biol Sci 2012; PubMed ID 22459616 Epub ahead of print
   Web of Science ®Google Scholar
• Hanada K, Furuya K, Yamamoto N, Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003;26(11):1563-9
   PubMed Web of Science ®Google Scholar
• Furuya K, Yamamoto N, Ohyabu Y, The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats. Biol Pharm Bull 2012;35(7):1096-104
   PubMed Web of Science ®Google Scholar
• Piu F, Gardell LR, Son T, Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol 2008;109:129-37
   PubMed Web of Science ®Google Scholar
• Schlienger N, Lund BW, Pawlas J, Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem 2009;52:7186-91
   PubMed Web of Science ®Google Scholar
• Miller CP, Shomali M, Lyttle CR, Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett 2011;2:124-9
   PubMed Web of Science ®Google Scholar
• Miller CP, Bhaket P, Muthukaman N, Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs). Bioorg Med Chem Lett 2010;20:7516-20
   PubMed Web of Science ®Google Scholar
• Schmidt A, Harada SI, Kimmel DB, Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem 2010;284:36367-76
   Web of Science ®Google Scholar
• Kim Y, Spencer KL, Hanney B, Preparation of carbonylamino-benzimidazoles as selective androgen receptor modulators. WO 2004041277; 2004
   Google Scholar
• Kim Y, Close J, Duggan ME, N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators. WO 2006060108; 2006
   Google Scholar
• Schmidt A, Kimmel DB, Bai C, Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem 2010;285:17054-64
   PubMed Web of Science ®Google Scholar
• Yarrow JF, Conover CF, McCoy SC, 17β -Hydroxyestra -4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol 2011;300:E650-60
   Web of Science ®Google Scholar
• Kanno Y, Hikosaka R, Zhang SY, (17α,20E)-17,20-[(1-Methoxyethylidene)bis (oxy)]-3-oxo-19-norpregna- 4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull 2011;34:318-23
   PubMed Web of Science ®Google Scholar
• Min L, Yanase T, Tanaka T, A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate. Endocrinol 2009;150:5606-16
   PubMed Web of Science ®Google Scholar
• Mitchell HJ, Dankulich WP, Hartman GD, Design, synthesis, and biological evaluation of 16-Substituted 4-azasteroids as tissue-selective androgen receptor modulators (SARMs). J Med Chem 2009;52:4578-81
   PubMed Web of Science ®Google Scholar
• A study of the safety and efficacy of MK-0773 in women with sarcopenia. Available from: http://clinicaltrials.gov/ct2/show/NCT00529659
   Google Scholar
• Levy N, Tatomer D, Herber CB, Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008;22(2):287-303
   PubMed Web of Science ®Google Scholar
• Ball LJ, Levy N, Zhao X, Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 2009;299(2):204-11
   PubMed Web of Science ®Google Scholar
• Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endoc 2010;204:105-14
   PubMed Web of Science ®Google Scholar
• Buijsman RC, Hermkens PH, van Rijn RD, Teerhuis NM. Non-steroidal steroid receptor modulators. Curr Med Chem 2005;12:1017-75
   PubMed Web of Science ®Google Scholar
• Wright AS, Douglas RC, Thomas LN, Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinol 1999;140:4509-15
   PubMed Web of Science ®Google Scholar
• Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992;21:309-14
   Google Scholar
• Tsugaya M, Harada N, Tozawa K, Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int J Urol 1996;3:292-6
   PubMedGoogle Scholar
• Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45-71
   PubMed Web of Science ®Google Scholar
• He Y, Yin D, Perera M, Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem 2002;37:619-34
   PubMed Web of Science ®Google Scholar
• Narayanan R, Coss CC, Yepuru M, Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008;22(11):2448-65
   PubMed Web of Science ®Google Scholar
• Obligacion R, Murray M, Ramzan I. Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl 2006;27:138-50
   PubMed Web of Science ®Google Scholar
• Barbier O, Be´langer A. Inactivation of androgens by UDP-glucuronosyl- transferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:259-70
   PubMed Web of Science ®Google Scholar
• Kim J, Wu D, Hwang DJ, The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 2005;315:230-9
   PubMed Web of Science ®Google Scholar
• Gao W, Reiser PJ, Coss CC, Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinol 2005;146(11):4887-97
   PubMed Web of Science ®Google Scholar
• Nobes JP, Langley SEM, Klopper T, A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012;109:1495-502
   PubMed Web of Science ®Google Scholar
• Singh R, Artaza JN, Taylor WE, Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinol 2006;147:141-54
   PubMed Web of Science ®Google Scholar
• Pihlajamaa P, Zhang FP, Saarinen Li, The phytoestrogen genistein is a tissue -specific androgen receptor modulator. Endocrinol 2011;152:4395-405
   PubMed Web of Science ®Google Scholar
• Allioli N, Vincent S, Vlaeminck-Guillem V, TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. Prostate 2011;71:1239-50
   PubMed Web of Science ®Google Scholar
• Kerry MJ, Lee SB, Nicole HI, Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes 2012;61:1072-81
   PubMed Web of Science ®Google Scholar
• Asthana S, Bhasin S, Butler RN, Masculine vitality: pros and cons of testosterone in treating the andropause. J Ger A Biol Sci Med Sci 2004;59:461-5
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Pluchino N. Androgen replacement therapy and cardiovascular function. Climacteric 2009;12:102-7
   PubMed Web of Science ®Google Scholar
• Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opin Emerging Drugs 2009;14:619-32
   PubMed Web of Science ®Google Scholar
• Dodson S, Baracos VE, Jatoi A, Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011;62:265-79
   PubMed Web of Science ®Google Scholar
• Anonymous. Contraceptive efficacy of testosterone-induced azoospermia in normal Men. World health organization task force on methods for the regulation of male fertility. Lancet 1990;336:955-9
   PubMedGoogle Scholar
• Anonymous. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal Men. World health organization task force on methods for the regulation of male fertility. Fertil Steril 1996;65:821-9
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS. Male hormonal contraception. Am J Obstet Gynecol 2004;190:S60-8
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS. Male contraception in the 21st century. Endocr Updates 1999;5:303-19
   Google Scholar
• Sharpe RM, Donachie K, Cooper I. Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the rat. J Endo 1988;117:19-26
   PubMed Web of Science ®Google Scholar
• Bradley AD. Update on the development of male hormonal contraceptives. Curr Opin Investig Drugs 2007;8:318-23
   PubMed Web of Science ®Google Scholar
• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44
   PubMed Web of Science ®Google Scholar
• Buena F, Swerdloff RS, Steiner BS, Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993;59:1118-23
   PubMed Web of Science ®Google Scholar
• Ansong KS, Punwaney RB. An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive. J Urol 1999;162:719-21
   PubMed Web of Science ®Google Scholar
• Davidson JM, Chen JJ, Crapo L, Hormonal changes and sexual function in aging men. J Clin Endo Met 1983;57:71-7
   PubMed Web of Science ®Google Scholar
• Johannes CB, Araujo AB, Feldman HA, Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-3
   PubMed Web of Science ®Google Scholar
• Carani C, Bancroft J, Granata A, Testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. Psychoneuroendocrinology 1992;17:647-54
   PubMed Web of Science ®Google Scholar
• Shah NM, Pisapia DJ, Maniatis S, Visualizing sexual dimorphism in the brain. Neuron 2004;43(3):313-19
   PubMed Web of Science ®Google Scholar
• Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril 2004;82:273-89
   PubMed Web of Science ®Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-52
   PubMed Web of Science ®Google Scholar
• Allan GF, Tannenbaum P, Sbriscia T, A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007;32:41-51
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabe Rev 2012;8:131-43
   PubMedGoogle Scholar
• Isidori AM, Giannetta E, Greco EA, Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005;63:280-93
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-33
   PubMed Web of Science ®Google Scholar
• Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama 2008;299:39-52
   PubMed Web of Science ®Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, Clinical review: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Miller MG, McWhirter CL, Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010;33:1186-92
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7
   PubMed Web of Science ®Google Scholar
• Bauer JM, Sieber CC. Sarcopenia and frailty: a clinician's controversial point of view. Exp Gerontol 2008;43:674-8
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argiles J, Cachexia: a new definition. Clin Nutr 2008;27:793-9
   PubMed Web of Science ®Google Scholar
• Hersberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953;83(1):175-80
   PubMed Web of Science ®Google Scholar
• Nejishima H, Yamamoto N, Suzuki M, Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia. Prostate 2012;72:1580-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Li X, Allan GF, Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. J Med Chem 2007;50:3857-69
   PubMed Web of Science ®Google Scholar
• Allan GF, Sbriscia T, Linton O, A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. J Steroid Biochem Mol Biol 2008;110:207-13
   PubMed Web of Science ®Google Scholar
• Smithkline Beecham, Co. Chemical Compounds. WO 2008121602; 2008
   Google Scholar